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Obesity is a worldwide growing problem. When confronted with obesity, many health
care providers focus on direct treatment of the consequences of adiposity. We plead
for adequate diagnostics first, followed by an individualized treatment. We provide
experience‐based and evidence‐based practical recommendations (illustrated by clin-
ical examples), to detect potential underlying diseases and contributing factors. Adult
patients consulting a doctor for weight gain or obesity should first be clinically
assessed for underlying diseases, such as monogenetic or syndromic obesity, hypo-
thyroidism, (cyclic) Cushing syndrome, polycystic ovarian syndrome (PCOS),
hypogonadism, growth hormone deficiency, and hypothalamic obesity. The most
important alarm symptoms for genetic obesity are early onset obesity, dysmorphic
features/congenital malformations with or without intellectual deficit, behavioral
problems, hyperphagia, and/or striking family history. Importantly, also common con-
tributing factors to weight gain should be investigated, including medication (mainly
psychiatric drugs, (local) corticosteroids, insulin, and specific β‐adrenergic receptor
blockers), sleeping habits and quality, crash diets and yoyo‐effect, smoking cessation,
and alcoholism. Other associated conditions include mental factors such as chronic
stress or binge‐eating disorder and depression.Identifying and optimizing the underly-
ing diseases, contributing factors, and other associated conditions may not only result
in more effective and personalized treatment but could also reduce the social stigma
for patients with obesity.
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Obesity (body mass index [BMI] ≥30.0 kg/m2) is a chronic disease1
that is a worldwide growing problem.2 In 2015, over 603 million adults
had obesity, and 4.0 million deaths were yearly accountable to a high
BMI.3 When facing a patient with obesity, most clinicians focus on- - - - - - - - - - - - - - - - - - - - - - - - - - -
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y John Wiley & Sons Ltd on behaltreating the associated comorbidities and/or simply recommend
weight loss. The diagnostic phase, which is typically used when
assessing other clinical problems, is often overlooked in obesity.
Whereas in other clinical problems, such as hypertension, clinicians
are alert to consider a wide variety of secondary causes.4 For obesity,
a diagnostic phase to detect underlying diseases or other factors that- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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796 VAN DER VALK ET AL.hinder weight loss is recommended by some5 but not all clinical prac-
tice guidelines. The European guideline recommends a diagnostic
phase; however, specific examples of diseases or factors that may
contribute to obesity are lacking.5 Others do not mention the neces-
sity to identify underlying contributing factors.6,7 This paper aims to
help clinicians to deepen the diagnostic phase with a comprehensive
overview of possible contributors to weight gain for an individual.
Currently, on a societal level, it is widely believed that obesity is sim-
ply the consequence of overconsuming unhealthy foods and lack of
exercise. However, on an individual level, there are many other contrib-
uting factors or underlying diseases, which are often not identified and
may prove significantly associated with weight gain and barriers to
weight loss. We suggest that clinicians should first detect and address
underlying diseases and contributing factors, before starting obesity
treatment. Besides lifestyle‐related factors, other factors include hor-
monal and genetic abnormalities, mental and socio‐cultural factors, and
side effects of medications. Identifying these underlying factors may lead
to more personalized treatment strategies, can also increase patients'
understanding of their obesity, and reduce their social stigma.1.1 | Clinical presentation
1.1.1 | Clinical Case A
A 66‐year‐old man, known with type 2 diabetes mellitus and eczema,
was referred because of obesity. Since the last decade, he became
increasingly heavier, with a rapid weight gain of 30 kg in the last year.
He noticed red striae under his armpits and suffered frommood swings
and decreased libido. A detailed past medication list showed several
episodes of using clobetason cream, triamcinolone, desoximetason,
and one short course of prednisone in the last 8 years. Moreover, in
the last year, he had used large amounts of mometason cream on his
whole back and arms because of severe eczema. We saw a man
weighing 168 kg (BMI 59.5 kg/m2) with pronounced abdominal obesity
with purple striae, hematomas, and severe non‐pitting ankle edema.
Laboratory results are shown inTable 1. We concluded that there was
severe obesity, with multiple contributing causes: an exogenous Cush-
ing syndrome due to the use of large amounts of dermal corticosteroids,
late‐onset hypogonadism (which can be a consequence of obesity but
also poses an opportunity for treatment8), and non‐pitting lymph-
edema. The subclinical hypothyroidism was considered a consequence
of obesity.9,10 A multidisciplinary strategy comprised gradual taperingTABLE 1 Laboratory results patient 1
Value
Reference
Value
TSH 6.030 mU/L 0.4‐4.3 mU/L
FT4 15.4 pmol/L 11‐25 pmol/L
Urinary cortisol first measurement 39 nmol/24 h 5‐133 nmol/24 h
Urinary cortisol second
measurement
48 nmol/24 h
Testosterone 5.05 nmol/L 10‐30 nmol/L
SHBG 40 nmol/L 10‐70 nmol/L
Calculated free testosterone 0.0839 nmol/L >220 pmol/La
aIn the presence of symptoms.93of topical corticosteroids and lymphedema compression therapy by
his dermatologist, testosterone supplementation, and an exercise
program. After 2 years, he had lost 35 kg, his clinical condition
improved, and testosterone and TSH levels had normalized. This case
shows the importance of a combined approach taking into account all
factors that contribute to obesity and counteract weight loss.
1.1.2 | Clinical Case B
A 48‐year‐old woman was referred because of severe obesity with type
2 diabetes, with no long‐term effect of previous diets. Her overweight
started around her first year of life, and later she had been treated in a
mental health institute for her eating behavior. Since she was a baby,
she always had an increased appetite. Several family members, mostly
from her mother's side, had obesity. Interestingly, she reported that even
during the Dutch extreme famine of 1945, her maternal grandfather had
obesity. We saw a woman with red hair, weighing 117 kg (BMI 41.5 kg/
m2). No other physical abnormalities were found.
We suspected a monogenetic cause of her obesity, because of the
young age of onset, hyperphagia, red hair, and family history. Diagnos-
tic screening of 52 obesity associated genes revealed two mutations in
the melanocortin 4 receptor gene (MC4R) gene, of whom one is known
to be pathogenic (c.[105C > A], p.[Tyr35*]), whereas the other is a var-
iant of unknown significance (VUS). Her daughter, who had obesity
since the age of three, had inherited bothMC4Rmutations. Her father,
who developed obesity at an older age, had no MC4R mutations.
In patients with pathogenic MC4R mutations long‐term weight
maintenance is difficult to achieve.11 The response to bariatric surgery
seems to be positive; however, long‐term results are still being inves-
tigated.12 Additionally, new pharmacological treatment options are
arising that target MC4R.13 Recently, effective pharmacological treat-
ment for another type of monogenetic obesity, caused by pathogenic
POMC gene mutations, has become available.14 It is therefore relevant
to identify underlying monogenic causes of obesity, which also may
reduce the patient's obesity stigma.2 | METHODS
Due to the comprehensive nature of the subject, we selected sub-
topics based on clinical experience. For each subtopic, we searched
databases such as the Cochrane library (February 2018) and MEDLINE
library for relevant articles. We preferably selected publications of the
last 5 years. Older publications were included if commonly referenced,
highly regarded, or relevant to the topic. Reference lists of relevant
identified articles were also searched.3 | ASSESSMENT OF OBESITY—CLINICAL
HISTORY
Weight gain occurs when the energy homeostasis is chronically “out of
balance.” This occurs either due to changes in total energy intake or in
total energy expenditure, the latter being the sum of a person's resting
energy expenditure plus a person's thermogenesis during activities.15 A
clinical consult addressing obesity should therefore focus on what
FIGURE 1 Recognizing underlying causes of obesity in adults. ADD, attention deficit disorder; PCOS, polycystic ovarian syndrome; MC4R,
melanocortin 4 receptor; POMC, proopiomelanocortin; PPI, proton pump inhibitors; OC, oral contraceptives; OSA, obstructive sleep apnea; OSFED,
other specified feeding and eating disorders [Colour figure can be viewed at wileyonlinelibrary.com]
VAN DER VALK ET AL. 797causes this excess and what maintains it. Examples to guide the clinical
approach of identifying underlying causes and contributing factors,
roughly grouped in lifestyle‐related factors, medication, (neuro‐)endo-
crine factors, genetic factors, and mental factors, are shown in Figure 1.3.1 | Lifestyle‐related factors involved in weight gain
Globally, the obesity pandemic is largely the consequence of increased
energy consumption.16 However, in individual patients, there may be
several reasons why a person has an increased caloric intake or
decreased energy expenditure, which may even be modifiable. Often,
there is a complex interplay of multiple social, psychological, and biolog-
ical factors altogether resulting in excess energy intake.
For example, in some cultures, exorbitant amounts of food are asso-
ciated with hospitality. Also, some patients may be unable to prioritize
weight management in light of financial problems, relationship issues,
or other circumstances requesting their attention. On an individual level,
patients may overeat because they experience increased hunger or
appetite. For example, this occurs in patients who have been on very
low calorie‐diets without exercise or behavioral therapy, often referred
to as the “yo‐yo‐effect.” The weight regain that follows may be associ-
ated with altered “hunger hormones” (eg, ghrelin) and satiety hormones'
(eg, leptin and peptide YY [PYY]) that can remain altered even a year
after ending the diet.17 Some individuals may overeat as a coping strat-
egy for other, psychological factors such as emotions.18Next, a
decreased quantity or quality of sleep can induce weight gain.19 This
may lead to a desire for high caloric food,20 imbalance of appetite hor-
mones (eg, ghrelin and leptin),21 as well as increased hypothalamic–pitu-
itary–adrenal‐axis reactivity22 yielding higher cortisol levels which may
also enhance obesity.23,24 Circadian misalignment, such as in shift work,
is associated with a decreased daily energy expenditure and increased
caloric intake.25,26 As for sleep quality, obstructive sleep apnea (OSA)is especially notable as it seems to have a bidirectional relation with obe-
sity. OSA occurs more frequently in obesity, but the sleep disturbances
belonging to it may again promote weight gain enhancing behavioral,
metabolic, and/or hormonal.27 It is not fully clear whether OSA treat-
ment has an effect on body weight.28-30
When there is no notable change in energy intake, the problem
may be altered energy expenditure, which can be either the result of
decreased activity or decreased resting metabolism.
Recently, several possible influencers of resting metabolism have
been identified. For example, weight loss itself can already affect the
total energy expenditure, as this decreases more than is expected from
the change in body composition only. This may be due to adaptive ther-
mogenesis, that may hinder further weight loss.31 Also, an important
contributor to a decreased metabolism is a sedentary lifestyle.32 Inter-
esting associations have been found for options to interrupt the contin-
uous sitting, eg, by intermittent standing, moving, or fidgeting, also
called nonexercise activity thermogenesis (NEAT).33 Another possible
determinant and future target regarding resting energy expenditure is
the activity of brown adipose tissue (BAT).34 BAT, which was found
to be also present in adult humans and basically burns calories into heat,
can be stimulated by physical activity or cold exposure. This has been
shown to result in a significant decrease in fat mass, with maintenance
of lean mass.35 Nicotine can also stimulate BAT,36 possibly explaining
the subtle weight gain that patients who quit smoking experience
(together with increased appetite and psychological factors). Impor-
tantly, this modest weight gain does usually not outweigh the beneficial
effects of smoking cessation. Education and guidance may limit the
weight gain when patients quit smoking.37
3.2 | Medication
Medication can affect the energy homeostasis mainly by promoting
hunger or by decreasing resting metabolism. In our clinical experience,
798 VAN DER VALK ET AL.we find it helpful to taper or stop medication with weight gaining
effects38 prior to a weight‐reducing intervention, as this may enhance
the weight reduction. An overview of medication that may induce
weight gain is provided in Table 2.
Drugs that are frequently used in psychiatry, such as specific
selective serotonin reuptake inhibitors or antipsychotic agents, are
well‐known to promote weight gain. The strongest weight change is
seen in amitriptyline, mirtazapine, and paroxetine.39 As for
antipsychotic drugs, olanzapine and clozapine induce the highest
weight gain.40 Also, several anti‐epileptic drugs should be noted.
Although most prescribers are aware of these side effects, in patients
with severe obesity, a medication switch to less obesogenic drugs
should be considered if possible.38
It is well‐known that systemic corticosteroids can cause weight
gain. For the treatment of rheumatoid arthritis, for example, it was
found that low‐dose prednisone is associated with a weight increase
of 4% to 8%.41 Corticosteroids can be administered in many forms.
Often overlooked are the local forms, which we recently reported to
be associated with increased BMI and waist circumference when
compared with non‐corticosteroid users in a large population‐based
cohort.42 Local corticosteroids may also have systemic effects resulting
in weight gain, in a similar matter as local corticosteroids having other
systemic effects, such as adrenal insufficiency,43 which needs further
research. A weight gaining systemic effect of local corticosteroids isTABLE 2 Drugs that may induce weight gain
Drug Class Examples of Specific Agents Estimated Weight G
Antidepressants Citalopram 26% higher chance
Mean weight gain d
Mirtazapine 50% higher chance
Mean weight gain 2
Amitryptilline 17% higher chance
Mean weight gain 2
Paroxetine Mean weight gain a
5% higher chance of
Antipsychotics Olanzapine 3.8 kg to 16.2 kg in
29% increases ≥7%
Lithium 4‐12 kg weight incre
Clozapine 0.9‐9.5 kg in youth
Quetiapine 2.3‐6.1 kg in youth
25% increases ≥7%
Risperidon 1.9‐7.2 kg in youth
18% increases ≥7%
Ziprasidone 9.8% increases ≥7%
Anti‐epileptics Carbamazepine 7‐15 kg weight gain
Gabapentin 57% gains ≥5% of b
Valproic acid 47% gains >10% of
0.5‐6 kg weight gain
Anti‐diabetics Insulin 1.78‐6 kg weight ga
SU derivates 2‐4 kg over 1 year o
Anti‐hypertensives α‐Adrenergic blockers 0.4‐2.0 kg
Β‐Adrenergic blockers 1.2‐kg mean weight
Corticosteroids Systemic corticosteroids Depending on doses
Rheumatoid arthritis
70% of patients rep
Local corticosteroids Unknown
association of highe
Others Proton pump inhibitors Possible association
Protease inhibitors Lipodystrophy
Average weight gain
Anti‐histamines Association with higlikely in patients using large quantities on a frequent basis, particularly
if they show additional Cushingoid features, such as abdominal obesity,
peripheral atrophy, plethora, and purple striae, as demonstrated by clin-
ical case A.
The initiation of insulin therapy or sulphonylurea derivates in
patients with type 2 diabetes can be accompanied by weight gain.38
Blood‐glucose lowering drugs without weight inducing effects, such
as glucagon‐like peptide‐1 analogues, metformin, and sodium‐glucose
cotransporter‐2 inhibitors,38 can be good alternatives if weight loss is
desired.
Other drugs that have been shown to induce obesity are non‐
selective β‐adrenergic receptor blockers.38,44 If prescribed for hyperten-
sion, one could consider replacing them with other antihypertensive
agents such as ACE‐inhibitors or angiotensin receptor blockers.44 The
weight increase is more profound in metoprolol than in carvedilol. Inter-
estingly, the weight increase was worse in subjects who already had
severe obesity.45,46 In HIV patients, the start of protease inhibitors has
also been associatedwithweight gain and increased deposition of visceral
adipose tissue.38 Another association has been found in users of H1 anti-
histamines, who were more likely to be overweight than non‐users.47
Regarding hormonal contraceptives, there is no large effect on
weight, although available evidence is insufficient.48 However, we
cannot rule out that some women experience excessive weight gain
due to individual differences.aining‐Effect per Agent References
of an episode of 5% weight gain
uring >4 months of treatment 1.69 kg
38,39,94
of an episode of 5% weight gain
.59 kg during >4 months treatment
of an episode of 5% weight gain
.24 kg durine >4 months treatment
fter >4 months of treatment 2.73 kg
an episode of 5% weight gain
youth
in body weight
38,40,95,96
ase
in body weight
in body weight
in body weight
38,96,97
aseline weight
baseline weight, 24% gains 5‐10% weight
on average
in in the first year 96,98,99
f treatment
100
difference when compared with other antihypertensives 44
, indication, and large individual variation
: weight increase 4% to 8%
ort weight gain
38,101
r BMI in women
42
with weight gain 50,102,103
8kg in a study of 10 patients
38,104,105
her weight and waist circumference 38,47,103
VAN DER VALK ET AL. 799Also, for several other agents, such as proton pump inhibitors and
alpha blockers, weight gaining effects have been reported.49,503.3 | Genetic causes of obesity
An overview of (mono)genetic obesity disorders is summarized in
Table 3. The genetics of obesity are complex. In the general popula-
tion, the fat‐mass and obesity associated gene (FTO) has shown the
strongest association to obesity.51 Besides these polygenic associa-
tions that have not been fully elucidated as yet, only a small percent-
age of the patients with obesity can be classified as having a
monogenic or syndromic obesity disorder.52
Screening for these conditions is not routinely done in clinical
practice. As new therapies are arising that target specific types of
obesity, we here plead for screening for genetic obesity in a sub-
group of patients who have a high clinical suspicion for these types
of genetic obesity. A recent study found a confirmed diagnosis of
genetic obesity in 3.9% of patients who were clinically suspected
of genetic obesity.53 Indications for genetic screening include an
early age of onset, below 5 years of age,54,55 (or in adult populations
a prepubertal onset), a family history with striking weight differences
between family members (which may indicate monogenic obesity),
and severe hyperphagia (which can be seen in monogenetic
obesity‐with and without intellectual deficit). Furthermore, character-
istics such as intellectual deficit or developmental delay, congenital
malformations, visual impairment and/or deafness, and abnormal
growth parameters (head circumference and height) may be indica-
tive for syndromic obesity. Examples of syndromic obesity are
Prader‐Willi syndrome (characterized by hypotonia and feeding prob-
lems in infancy, and later in life hyperphagia and obesity, short stat-
ure, intellectual deficit and hypogonadotropic hypogonadism56),
Bardet‐Biedl syndrome (intellectual deficit, retinal dystrophy or pig-
mentary retinopathy, polydactyly, hypogonadism, and nephropathy),
and the 16p11.2 deletion syndrome (intellectual deficit, speech
development problems, autism, macrocephaly, and epilepsy). There
is a large variability of these symptoms among affected patients.57
Mild to moderate intellectual disability is also seen in patients with
pseudohypoparathyroidism type 1 (PHP1a), caused by maternally
inherited heterozygous mutations in GNAS. PHP1a is associated with
the clinical phenotype of Albright's hereditary osteodystrophy (AHO),
which encompasses short stature, round facies, and skeletal
abnormalities58
Monogenic (non‐syndromic) causes of obesity are characterized
by a young age of onset and hyperphagia,12,54 with usually no intellec-
tual deficit. Additionally, other clinical signs of monogenetic obesity
may differ depending on the affected gene. These include red or ruddy
hair, pale skin, and adrenocorticotropic hormone (ACTH) deficiency
(pro‐opiomelanocortin [POMC] gene defects), central hypothyroidism,
hypogonadotropic hypogonadism and frequent infections (leptin defi-
ciency, caused by autosomal recessive LEP gene mutations), increased
linear growth and increased lean mass, severe hyperinsulinemia, and
mild central hypothyroidism (caused by autosomal dominant or reces-
sive MC4R mutations) and neonatal diarrhea, recurrent hypoglycemia,and global endocrine dysfunction (caused by prohormone convertase‐
1 [PCSK1] mutations).54,593.4 | Neuroendocrine causes
3.4.1 | Hormonal causes
A relatively sudden increase in weight may suggest a neuroendocrine
cause. We screen for hypothyroidism, as this is associated with a mod-
est weight gain. This is especially recommended if patients present
with other symptoms such as dry skin, feeling cold, etc. However,
the weight gain in hypothyroidism seems mostly due to additional
edema.60 Also, obesity is often associated with a slightly increased
TSH that is most often the result of excess adipose tissue rather than
the cause of obesity. This can be explained by the presence of periph-
eral thyroid resistance and also by increased levels of leptin, stimulat-
ing TRH and subsequently TSH.9,10 Weight loss usually reverses this
form of hyperthyrotropinemia.61
To identify Cushing syndrome (CS), specific signs of CS including
easy bruising, facial plethora, proximal myopathy, and recent purple
striae62 should be considered, as most patients with obesity will have
the more non‐specific CS signs such as central obesity, fatigue, hyper-
tension, and decreased libido. Due to the large number of corticoste-
roid users,63,64 iatrogenic CS should also be considered.
Another common endocrine condition associated with obesity is
the polycystic ovarian syndrome (PCOS), a constellation of
hyperandrogenism, oligoovulation or anovulation, and polycystic ova-
ries. Male hypogonadism has a complex, bidirectional relation with
obesity. Testosterone therapy in patients with obesity or diabetes
with evident testosterone deficiency causes improvement of body
composition and components of the metabolic syndrome.8,65 On the
other hand, obesity induces hypogonadotropic hypogonadism, and a
healthy diet and physical activity can increase bound and unbound
testosterone levels and completely normalize the hypogonadism.66
Women may report weight gain after pregnancy67 or meno-
pause.68 The average weight change from preconception to the first
year postpartum is referred to as “postpartum weight retention.” This
is on average relatively small (0.5 to 1.5 kg). However, there is a large
variability, as 13% to 20% of women are 5 kg or more above their pre-
conception weight by 1‐year postpartum.69 Although menopause is
frequently reported as a contributing factor by women, and experi-
mental evidence suggests estrogen depletion is associated with
abdominal fat accumulation, epidemiological evidence in humans indi-
cates that the steady weight gain of 0.5 kg annually is due to age
rather than the menopause itself.70
In specific patients with a history of pituitary disease, surgery or
irradiation in these areas, severe head trauma, or evidence of other
pituitary hormone deficiencies,71 endocrine evaluation is indicated,
including growth hormone (GH) deficiency as it may contribute to
obesity and treatment options are available.72,73
3.4.2 | Hypothalamic disorders
Hypothalamic obesity, typically accompanied by hyperphagia, can
occur after various insults leading to damage of the hypothalamic
T
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VAN DER VALK ET AL. 801region. It is seen in patients with abnormalities in the hypothalamic
region, eg, craniopharyngeoma (especially following surgery), inflam-
matory processes such as sarcoidosis and tuberculosis, vascular dam-
age, head trauma, or after cranial radiotherapy, but also some of the
genetic mutations that were previously mentioned can be considered
hypothalamic obesity.74 In severe cases, it can lead to multiple endo-
crine symptoms such as impaired reproductive function with amenor-
rhea or impotence, diabetes insipidus, and thyroid or adrenal
insufficiency (obesity that results in hormonal abnormalities is
discussed in the previous paragraph). Also, neurological symptoms
can be seen, including convulsions, hypothermia or hyperthermia, or
somnolence.753.5 | Mental factors
In patients with obesity, attention to mental factors should be paid.
Numerous studies showed that depression is linked to obesity, in a
bidirectional manner.76-78 This is not surprising, as changes in food
intake are considered symptoms of depression.79 The associations
are stronger for patients with a symptom profile that is often labeled
as “atypical.”78 Also, anxiety disorders are cross‐sectionally associated
with obesity.80
Binge‐eating disorder81 is characterized by recurrent binge‐eating
episodes where more food is consumed than is normal for most peo-
ple and where feelings of lack of control and distress play a role.
Importantly, binge‐eating can also be a sign of hyperphagia and may
thus be a diagnostic clue for either genetic or hypothalamic obesity,
as demonstrated in Clinical Case B.
Evidence is mounting that stress leads to more appetite (in com-
fort food), induces abdominal obesity,24 and may counteract the
effects of a healthy diet.82-84 Additionally, the weight stigma that indi-
viduals with obesity often suffer from may also lead to extra weight
gain.85 It is therefore conceivable that a non‐stigmatizing attitude, as
well as stress reduction, is beneficial when treating obesity.
Furthermore, events during early life have been identified as risk
factors for obesity. Adolescents with a history of childhood sexual
abuse have a higher risk of obesity (in men) or disordered eating (in
women)864 | LABORATORY DIAGNOSTICS AND
FURTHER EVALUATION
General laboratory evaluation can be considered in all patients with
obesity, including fasting glucose (and insulin in case of acanthosis
nigricans), lipids, liver enzymes, and thyroid screening (TSH, and FT4
on indication).5 In case of clinical clues, this can be extended by testing
gonadal function and/or Cushing diagnostics. Diagnostics for (mono)
genetic obesity should be reserved for individuals with a high clinical
suspicion (eg, early onset obesity, with or without intellectual deficit,
dysmorphic features/congenital malformations, behavioral problems,
hyperphagia, and/or striking family history, Figure 153).5 | SOCIETY‐RELATED OBESOGENIC
FACTORS AND FUTURE TARGETS FOR
PUBLIC HEALTH INTERVENTIONS
The assessment of obesity can be complicated further by considering
disruptors of energy homeostasis on a societal level. These currently
have limited value in clinical practice but are interesting possible tar-
gets for public health interventions. These include endocrine
disruptors, such as chemicals in pesticides/herbicides, industrial and
household products, plastics, detergents, flame retardants, and ingre-
dients in personal care products, that can affect the endocrine system
and interfere with various metabolic processes.87,88 In addition, both
low birthweight and high birthweight in boys and high birth weight
in girls have been associated to obesity,89 indicating that intra‐uterine
factors may be important to weight. Also, early childhood infections
have recently been shown to contribute to obesity.90 In this context,
an interesting emerging field of research is “infectobesity,” which is
the study of microbial agents as a cause of obesity. For example,
intriguing associations between obesity and the adenovirus‐36 have
been found.91 The changing gut microbiome seems more and more
important in the pathogenesis of obesity.926 | CONCLUSIONS
Obesity is a complex clinical problem where adequate diagnostics are
often overlooked. We plead for a comprehensive approach of obesity,
including adequate diagnostics prior to treatment. This includes,
besides evaluation of lifestyle factors, a detailed past and present
medical history, medication use, a global outline of the sociocultural
environment, and a thorough physical examination. In case of abnor-
malities suggestive of an underlying disease, we recommend specific
testing for these causes, as some conditions may be treatable. Further-
more, modifiable contributing factors, such as the use of weight
gaining medication, lack of sleep, chronic stress etc. may be optimized
before starting a lifestyle intervention or bariatric surgery. This may
lead to more effective treatment for individuals with obesity. Addi-
tionally, knowing the cause of the obesity can help to reduce the social
stigma that many individuals with obesity suffer from.ACKNOWLEDGEMENTS
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